Effects of Serelaxin in Patients with Acute Heart Failure

In a randomized trial, 6545 patients with acute heart failure were assigned to either serelaxin or placebo in addition to standard care. There were no significant differences between the two groups in the incidence of death from cardiovascular causes at 180 days or worsening heart failure at 5 days.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-08, Vol.381 (8), p.716-726
Hauptverfasser:	Metra, Marco, Teerlink, John R, Cotter, Gad, Davison, Beth A, Felker, G. Michael, Filippatos, Gerasimos, Greenberg, Barry H, Pang, Peter S, Ponikowski, Piotr, Voors, Adriaan A, Adams, Kirkwood F, Anker, Stefan D, Arias-Mendoza, Alexandra, Avendaño, Patricio, Bacal, Fernando, Böhm, Michael, Bortman, Guillermo, Cleland, John G.F, Cohen-Solal, Alain, Crespo-Leiro, Maria G, Dorobantu, Maria, Echeverría, Luis E, Ferrari, Roberto, Goland, Sorel, Goncalvesová, Eva, Goudev, Assen, Køber, Lars, Lema-Osores, Juan, Levy, Phillip D, McDonald, Kenneth, Manga, Pravin, Merkely, Béla, Mueller, Christian, Pieske, Burkert, Silva-Cardoso, Jose, Špinar, Jindřich, Squire, Iain, Stępińska, Janina, Van Mieghem, Walter, von Lewinski, Dirk, Wikström, Gerhard, Yilmaz, Mehmet B, Hagner, Nicole, Holbro, Thomas, Hua, Tsushung A, Sabarwal, Shalini V, Severin, Thomas, Szecsödy, Peter, Gimpelewicz, Claudio
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Adaptation Aged Blood pressure Blood Pressure - drug effects Body weight Cardiovascular Diseases - mortality Committees Congestive heart failure Death Design Disease Progression Double-Blind Method Dyspnea Female Heart failure Heart Failure - drug therapy Heart Failure - mortality Heart Failure - physiopathology Hospitalization Humans Incidence Infusions, Intravenous Intravenous administration Kidneys Life Sciences Male Mortality Patients Peptides Pregnancy Radiography Recombinant Proteins - adverse effects Recombinant Proteins - pharmacology Recombinant Proteins - therapeutic use Relaxin Relaxin - adverse effects Relaxin - pharmacology Relaxin - therapeutic use Renal failure Renal insufficiency Respiration Treatment Failure Vasodilator Agents - adverse effects Vasodilator Agents - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a randomized trial, 6545 patients with acute heart failure were assigned to either serelaxin or placebo in addition to standard care. There were no significant differences between the two groups in the incidence of death from cardiovascular causes at 180 days or worsening heart failure at 5 days.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1801291